Copyright
©2014 Baishideng Publishing Group Co.
World J Diabetes. Feb 15, 2014; 5(1): 69-75
Published online Feb 15, 2014. doi: 10.4239/wjd.v5.i1.69
Published online Feb 15, 2014. doi: 10.4239/wjd.v5.i1.69
Table 2 Treatment algorithms used in this study
Initial dose | BMI | Algorithms | |||
LANMET fixed | LANMETPlus | DeGold fixed | DeGoldPlus | ||
Fixed initial dose in U | n.a. | 10 | 10 | ||
Variable dose according to | < 26 | 0.2 | 0.2 | ||
BMI (kg/m2) in U/kg | 26 < 30 | 0.25 | 0.25 | ||
30 < 35 | 0.3 | 0.3 | |||
> 35 | 0.35 | 0.35 | |||
Insulin adjustment | FPG | ||||
Fixed Titration twice/week in U | 2 | 2 | |||
Variable titration according to | < 100 | 0 | 0 | ||
FPG (mg/dL) twice/week in U | 101 < 120 | -2 | -2 | ||
121 < 140 | 2 | 2 | |||
141 < 180 | 4 | 4 | |||
> 180 | -2 | -2 |
- Citation: Franco DR, Baptista J, Abreu FR, Batista RB, Eliaschewitz FG. Starting glargine in insulin-naïve type 2 diabetic patients based on body mass index is safe. World J Diabetes 2014; 5(1): 69-75
- URL: https://www.wjgnet.com/1948-9358/full/v5/i1/69.htm
- DOI: https://dx.doi.org/10.4239/wjd.v5.i1.69